Author Archives: Gastroenterology Journal
Reply to Letters to the Editor on Probiotic Guidelines
Beneficial effect of tacrolimus … Cyclosporin A, still up for discussion!
Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 1: Live Vaccines
Patients with inflammatory bowel disease (IBD) may be at increased risk of some vaccine-preventable diseases. The effectiveness and safety of vaccinations may be altered by immunosuppressive therapies or IBD itself. These recommendations developed by t… Continue reading
IL-33 and eosinophils link inflammation and metaplasia in a mouse model of chronic gastritis with intestinalizing features
Gastroparesis: a dead-end street after all?
The Colonic Mucosal MicroRNAs, MicroRNA-219a-5p and MicroRNA-338-3p, are Downregulated in Irritable Bowel Syndrome and are Associated with Barrier Function and MAPK signaling
Alterations in microRNA (miRNA) and in the intestinal barrier are putative risk factors for irritable bowel syndrome (IBS). We aimed to identify differentially expressed colonic mucosal miRNAs, their targets in IBS compared to healthy controls (HCs), a… Continue reading
Association Between Collagenous and Lymphocytic Colitis and Risk of Severe COVID-19
Clinical Implications of colorectal cancer stem cells in the age of single-cell OMICs and targeted therapies.
The cancer stem cell (CSC) concept emerged from the recognition of inherent tumor heterogeneity and suggests that within a given tumor, in analogy to normal tissues, there exists a cellular hierarchy composed of a minority of more primitive cells with … Continue reading
Endoscopic Submucosal Dissection (ESD) in North America: A Large Prospective Multicenter Study
Endoscopic submucosal dissection (ESD) in Asia has been shown to be superior to endoscopic mucosal resection (EMR) and surgery for the management of selected early gastrointestinal cancers. We aimed to evaluate technical outcomes of ESD in North America. Continue reading
An international consensus to standardize integration of histopathology in ulcerative colitis clinical trials
Histopathology is an emerging treatment target in ulcerative colitis (UC) clinical trials. We aim to provide guidance on standardizing biopsy collection protocols, identifying optimal evaluative indices, and defining thresholds for histologic response … Continue reading